Get started
Author

Carlyn Rose Tan

Observed name: Carlyn R. Tan
ORCID: 0000-0001-7922-2594
Observed ORCID: 0000-0001-7922-2594
OpenAlex ID: A5124948268
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM
2026 · Kylee H. Maclachlan, Carlyn R. Tan, et al. · Blood Advances · 7
PDF
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
2026 · Carlyn Rose Tan, Saad Usmani, et al. · Blood Advances · 2
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
2026 · Enrique M. Ocio, Gurdeep Parmar, et al. · Expert Opinion on Drug Delivery · 1
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
2026 · Carlyn Rose Tan, Sham Mailankody · Nature Reviews Clinical Oncology
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
2026 · Enrique M. Ocio, Gurdeep Parmar, et al. · Figshare
Maintenance Therapy with Iberdomide Following Autologous Hematopoietic Cell Transplantation in Lenalidomide-Exposed Multiple Myeloma Patients
2026 · Natalia Tijaro Ovalle, Malin Hultcrantz, et al. · Transplantation and Cellular Therapy
Precision Melphalan Dosing Using a Population Pharmacokinetic Model Combined with IL-6 Blockade (Siltuximab) in Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation: Phase II Lead-in Outcomes
2026 · Natalia Tijaro Ovalle, Andrew Lin, et al. · Transplantation and Cellular Therapy
Works count: 7
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type